April 3, 2018 / 11:09 AM / 7 months ago

BRIEF-FDA Accepts Biologics License Application For Moxetumomab Pasudotox

April 3 (Reuters) - AstraZeneca PLC:

* US FDA ACCEPTS BIOLOGICS LICENSE APPLICATION FOR MOXETUMOMAB PASUDOTOX IN HAIRY CELL LEUKEMIA

* FDA GRANTED MOXETUMOMAB PASUDOTOX BLA PRIORITY REVIEW STATUS WITH A PRESCRIPTION DRUG USER FEE ACT DATE SET FOR Q3 OF 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below